Notorious drug CEO/record-album purchaser Martin Shkreli has lost one of those descriptors. He resigned as CEO of Turing Pharmaceuticals on Friday following his Thursday arrest for alleged securities fraud and conspiracy, and Monday brings the news that he's been terminated as CEO of KaloBios Pharmaceuticals, reports CNBC. Reuters reports the move was effective on the day of Shkreli's arrest, which was also the day the company halted trading; trading has yet to resume. Shkreli has additionally given up his seat on KaloBios' board.
But trading isn't the only thing that's been halted in relation to KaloBios. Bloomberg reports that a clinical leukemia drug trial sponsored by KaloBios has been suspended by the University of California at Davis and Florida's Moffitt Cancer Center. A number of additional institutions had also planned to participate—among them the Mayo Clinic and Weill Cornell Medical College. As of Saturday, they had yet to comment or announce a decision. (Read more Martin Shkreli stories.)